VivoSeq
Oncology

Malignant Tumor

1

Pipeline Programs↗

4

Active Trials↗

6

Companies Involved↗

Malignant Tumor is an early-stage landscape with 1 program across 6 companies. The most active players are Dragonboat Biopharmaceutical Company Limited, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing Sanhome Pharmaceutical, Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

89/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

D

Dragonboat Biopharmaceutical Company Limited

1 program

Phase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

0 programs

PreclinicalN

Nanjing Sanhome Pharmaceutical, Co., Ltd.

0 programs

PreclinicalQilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.

0 programs

PreclinicalCSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

0 programs

PreclinicalC

CSPC Megalith Biopharmaceutical Co.,Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

JS207

Shanghai Junshi Bioscience Co., Ltd.

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

21

clinical trials

Unknown status8 · 38%
Completed8 · 38%
Recruiting3 · 14%
Suspended1 · 5%
Active, not recruiting1 · 5%

Clinical Trials

Trial Activity

21 trials

Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Malignant Tumor
Recruiting·PPeking Union Medical College Hospital·N/A·NCT06844110·50 enrolled
A Clinical Trial of SIBP-A10 Injection in the Treatment of Advanced Malignant Tumor Subjects.
Recruiting·SShanghai Institute Of Biological Products·Phase 1·NCT07205198·160 enrolled
Evaluation of SYS6005 in Patients With Advanced Malignant Tumor
Recruiting·CCSPC Megalith Biopharmaceutical Co.,Ltd.·Phase 1·NCT06958679·132 enrolled
A Phase I Study to Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of JS207 in Patients With Advanced Malignant Tumor
Active, not recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 1·NCT06022250·98 enrolled
A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor
Completed·RRemeGen Co., Ltd.·Phase 2·NCT05628857·29 enrolled
Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy
Completed·—·N/A·NCT01906632·50 enrolled
Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients
Completed·SSichuan Cancer Hospital and Research Institute·Phase 3·NCT06007586·143 enrolled
A Clinical Study of TQB3912 Tablets in Patients With Advanced Malignant Tumor
Completed·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 1·NCT05997342·36 enrolled
Multisensory Therapy Alleviating MRI-Related Anxiety in Cancer Patients Via Brain-Autonomic Network Modulation: A Randomized Clinical Trial
Completed·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Preclinical·NCT07692412·152 enrolled
An Exploratory Clinical Study of Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined With Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1) in Patients With Advanced Malignant Tumor
Completed·DDragonboat Biopharmaceutical Company Limited·Phase 1·NCT04739111·12 enrolled
Systematic Oral Care Education for Preventing Oral Complications in Patients Undergoing Radiotherapy for Head and Neck Malignancies: A Randomized Controlled Trial
Completed·WWest China Hospital·Preclinical·NCT06690346·150 enrolled
A Multi-center Observational Clinical Study Observing the Differences of Tongue Images Between Patients With Malignant Tumors and Healthy People
Completed·ZZhejiang Cancer Hospital·N/A·NCT04793672·4,100 enrolled
A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor
Suspended·CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logoCSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 2·NCT05089461·120 enrolled
A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor
Unknown status·Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logoChia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT04412564·200 enrolled
Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Malignant Tumor
Unknown status·SSir Run Run Shaw Hospital·Phase 1·NCT03662815·30 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)